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Role of lipid control in diabetic nephropathy. Patients
with diabetic nephropathy are known to be associated with
many lipoprotein abnormalities, including higher plasma lev-
els of very low-density lipoprotein, low-density lipoprotein and
triglycerides, and lower levels of high-density lipoprotein. Many
studies have reported that lipids may induce both glomeru-
lar and tubulointerstitial injury through mediators such as
cytokines, reactive oxygen species, chemokines, and through
hemodynamic changes. Clinical studies in patients with diabetic
nephropathy showed that lipid control can be associated with
an additional effect of reduction in proteinuria. Experimen-
tal studies demonstrated that lipid-lowering agents exerted a
certain degree of renoprotection, through both indirect effects
from lipid lowering and a direct effect on cell protection. There-
fore, lipid control appears to be important in the prevention and
treatment of diabetic nephropathy.
Diabetic nephropathy has become the leading cause of end-
stage renal failure in many countries, including Taiwan. One of
the major risk factors for the development and progression of
diabetic nephropathy is dyslipidemia. In this paper we will re-
view the role of lipid in mediating renal injury and the beneficial
effects of lipid control in diabetic nephropathy.
LIPOPROTEIN ABNORMALITIES IN DIABETIC
NEPHROPATHY
Patients with diabetic nephropathy often have multiple
lipoprotein abnormalities [1]. In patients with microal-
buminuria and overt proteinuria, increased plasma lev-
els of very low-density lipoprotein (VLDL), low-density
lipoprotein (LDL), and triglycerides are usually found.
However, the plasma level of high-density lipoprotein
(HDL) is lower than those patients with normoalbu-
minuria. In addition to the abnormalities in amount of
lipoprotein, the diameter of LDL particles is also re-
ported to be smaller in patients with diabetic nephropathy
[2, 3] compared to diabetic patients without nephropa-
thy. All the lipoprotein abnormalities mentioned above
become more severe with declining renal function and
increasing albuminuria. In those diabetic patients with
nephrotic syndrome and advanced renal failure, the pat-
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terns of dyslipoproteinemia are not different from those
patients without diabetes.
Recent studies also suggest that apolipoprotein (apo)
E gene polymorphism may be important in the develop-
ment of diabetic nephropathy [4, 5]. Although results are
still conflicting, our study in Taiwanese patients demon-
strated that the frequency of apo E2 allele was signifi-
cantly higher in patients with diabetic nephropathy than
in normal controls and diabetics without nephropathy [6].
These findings imply that apo E polymorphism is appar-
ently related to the development of diabetic nephropathy
in type 2 diabetes in Taiwan.
LIPID-INDUCED RENAL INJURY IN DIABETIC
NEPHROPATHY
Dietary-induced hypercholesterolemia in animals in-
duced focal glomerulosclerosis [7], and lipid-lowering
treatment in Zucker rats was associated with atten-
uation in glomerular lesions [8]. Animal studies also
demonstrated a damaging effect of hyperlipidemia on
the tubulointerstitium [9], which is also a major feature
of diabetic nephropathy and an important predictor of
renal dysfunction [10]. Recent study demonstrating that
hyperlipidemia and hyperglycemia act synergistically to
induce renal injury in LDL receptor-deficient mice [11]
has further indicated that lipid can exacerbate diabetic
nephropathy. Dyslipidemia may also cause or exacerbate
diabetic nephropathy by alterations in the coagulation-
fibrinolytic system, changes in membrane permeability,
damage to endothelial cells, and increased atherosclero-
sis [12].
Clinical study on the correlation between hyperlipi-
demia and renal dysfunction in patients with diabetic
nephropathy is difficult due to the complex interrelation
between serum lipid, blood glucose, and proteinuria. In
a study on 53 normoalbuminuric type 1 diabetic patients,
Watts et al found that the development of microalbu-
minuria after 10 years’ follow-up was closely related to
baseline serum cholesterol and LDL cholesterol levels
[13]. Parving et al also found a close relationship be-
tween serum cholesterol level and the progression of re-
nal dysfunction in a 10-year prospective study in type 1
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diabetic patients with nephropathy [14]. In studies on pa-
tients with type 2 diabetes, baseline level of serum choles-
terol was also found to be the independent risk factor for
the development of diabetic nephropathy [15, 16]. How-
ever, conflicting results were found between the effects
of serum lipid on the progression of renal function in type
2 diabetes [17, 18].
The mechanisms by which lipid induced renal injury are
not clear. We have demonstrated that both native and ox-
idized LDL enhance superoxide production from freshly
isolated diabetic rat glomeruli [19], and the reactive oxy-
gen species enhances endothelin-1 production of diabetic
rat glomeruli in vitro and in vivo [20]. Other factors, such
as transforming growth factor-b1 (TGF-b1), were also
suggested to be an important mediator in lipid-induced
renal injury in diabetic nephropathy [21].
CLINICAL EFFECTS OF LIPID CONTROL IN
DIABETIC NEPHROPATHY
Although lipid-lowering treatment has been shown to
be effective in reducing cardiovascular morbidity and
mortality in diabetic patients with hyperlipidemia, their
effects on diabetic nephropathy are still unclear due
to lack of prospective randomized intervention studies.
Early studies have demonstrated that treatment with the
HMG CoA reductase inhibitor pravastatin decreases al-
buminuria in patients with type 2 diabetes [22, 23]. How-
ever, later studies showed either beneficial or no effects
on albuminuria with HMG CoA reductase inhibitors in
both type 1 or type 2 patients [24–27]. In general, these
studies involved only a small number of patients, and the
duration of follow-up was short, making it inadequate in
assessing the clinical effects of lipid control in diabetic
nephropathy.
EXPERIMENTAL STUDIES ON THE EFFECT OF
LIPID CONTROL IN DIABETIC NEPHROPATHY
Diabetic glomerulosclerosis is characterized by an in-
crease in mesangial matrix, and the close resemblance
on the pathogenesis of glomerulosclerosis to atheroscle-
rosis has led to the speculation that lipids are involved
in the development of diabetic nephropathy. We have
demonstrated that pravastatin suppresses the effects of
high glucose on the proliferation and the production of
superoxide and fibronectin of mesangial cells [28]. Since
both the proliferation and the increased superoxide pro-
duction of mesangial cells occur early during the progress
of diabetic nephropathy [29], early treatment with pravas-
tatin might postpone the progression of glomerular in-
jury in patients with diabetic nephropathy. Transforming
growth factor-b (TGF-b) may be an important media-
tor involved because high glucose causes an increase in
expression of TGF-b in the glomeruli of streptozotocin-
diabetic rats [30], and pravastatin suppresses the activ-
ity of TGF-b induced by high glucose [31]. Another
study also demonstrated that simvastatin prevents high
glucose-induced proliferation of mesangial cells via mod-
ulation of Rho GTAase/p21 signaling pathway [32], which
provides a molecular basis for the use of statins in early
stages of diabetic nephropathy.
We have also demonstrated that pravastatin suppresses
the effect of both LDL and oxidized-LDL on mesangial
cells [28, 33], which is important because an increased
plasma level of oxidized-LDL has been found in diabetic
patients [34], especially in those patients with macroal-
buminuria [35]. Our previous study has demonstrated
that the oxidative stress and the oxidative modification
of LDL can be effectively inhibited by insulin [36], sug-
gesting that insulin may have an additional effect to pre-
vent the generation of atherogenic lipoproteins in vivo.
There is accumulating evidence that statins have bene-
ficial effects that are independent of the classic actions
on lipid lowering [37]. These effects include: improving
endothelial function, reducing LDL oxidation, reducing
platelet aggregability, reducing procoagulation factors,
and inhibiting smooth muscle cell proliferation.
The mechanisms by which HMG-CoA reductase in-
hibitors reduce renal lesions remain unclear. Recent stud-
ies have suggested that metabolites of the mevalonate
pathway play a critical role in cell proliferation [38, 39].
Mevalonate is synthesized intracellularly from HMG-
CoA by the actions of HMG-CoA reductase [40]. Thus,
it is thought that inhibition of HMG-CoA reductase by
pravastatin leads to loss or significant reduction of meval-
onate, subsequently inhibiting DNA synthesis as well
as cell proliferation in several types of cells, including
mesangial cells. Since the inhibition of pravastatin on the
macrophage growth induced by oxidized-LDL is reversed
by the addition of mevalonate [41], its role in cell prolif-
eration is further implicated. Weiss et al have also shown
that short-term (1 hour) incubation of pravastatin induces
apoptosis of vascular smooth muscle cells [42], an effect
that may also be involved in the depletion of cell numbers
in diabetic glomerulosclerosis.
CONCLUSION
Dyslipidemia is common in diabetic patients. Many
clinical and experimental studies suggest that serum
cholesterol may play important role in the development
and progression of diabetic nephropathy. Although large-
scaled prospective, randomized, controlled studies are
still lacking, lipid control appears to be important in the
prevention and treatment of diabetic nephropathy.
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